This insider cluster is routine post-earnings option exercise-and-sell activity with no material signal. The dollar amount is negligible relative to market cap. Monitor the next 10-Q for any revenue trend deterioration following the Q2 top-line miss, but this insider activity alone does not warrant any trading action.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $529.66entry
- T+1 · 3mo ago −2.67%α −2.35% · $515.50
- T+5 · 3mo ago −4.00%α −3.95% · $508.48
- T+20 · 2mo ago −5.98%α −5.07% · $497.97
- T+60 · 14d ago +13.53%α +15.95% · $601.32
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Martine Rothblatt and EVP/GC Paul Mahon sold a combined ~$7.5M in open-market shares on August 6, 2026, the day after UTHR reported mixed Q2 results (revenue miss, EPS beat). Both insiders also exercised stock options (non-cash events) on the same day, indicating this is routine post-earnings option exercise-and-sell activity following the blackout window opening. At 0.033% of UTHR's $22.6B market cap, the dollar value is trivial and carries no material signal, the cluster is consistent with standard post-earnings insider selling patterns, not informed negative conviction.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold ~$3.2M in open-market shares on Aug 6, 2026
- EVP/GC Paul Mahon sold ~$4.3M in open-market shares on Aug 6, 2026
- Both insiders exercised stock options (non-cash) on the same day, Rothblatt 9,500 shares at $0, Mahon 8,300 shares at $146.03
- Total open-market sales of ~$7.5M represent only 0.033% of UTHR's $22.6B market cap
- Cluster occurred one day after UTHR's Q2 2026 earnings release (Aug 5), consistent with post-blackout-window opening
- Q2 revenue of $783.3M missed $804.6M consensus (-2% YoY); EPS of $7.27 beat $6.86 estimate
Financial Impact
Total insider open-market sales of ~$7.5M (0.033% of market cap), economically trivial
Risk Factors
- Revenue decline of 2% YoY in Q2 may signal competitive headwinds in inhaled prostacyclin market
- Tyvaso Nebulized sales dropped 18% YoY, partially offset by Tyvaso DPI growth
- No insider buying to offset the selling, consistent with lack of bullish conviction from management
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1786165565043 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers